Trending Topic

15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cardiovascular diseases are the most common cause of mortality and morbidity in adults worldwide.1 Coronary angiography (CAG) is the gold standard method for evaluating atherosclerotic coronary artery disease (CAD).2 It is conventionally performed via the trans-femoral (TF) route. Recently, however, the trans-radial (TR) route has become the preferred way.3 The TR route offers better procedure comfort, shorter hospitalization […]

Ole De Backer, TCT 2022: FEops HEARTguide™ Computational Modelling for left atrial appendage (LAA) closure, the PREDICT LAA trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 4th 2022

The PREDICT LAA trial aimed to examine whether cardiac computed tomography- based FEops HEARTguide™ computational modelling would benefit clinical outcomes when planning for left atrial appendage (LAA) closure. In this touchCARDIO interview, we speak with Dr Ole De Backer (Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark) to discuss the PREDICT LAA trial and the next steps. 

The abstract entitled ‘The Value of FEops HEARTguide™ Computational Modeling in the Planning of Percutaneous LAA Closure: The PREDICT LAA Trial’ was presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, 16 – 19, September 2022.

Questions:

  1. What were the aims, design and eligibility criteria of the PREDICT LAA Trial? (0:18)
  2. What were the primary and secondary endpoints and how well were they achieved? (1:26)
  3. What questions remain unanswered and what future studies are planned? (4:56)

Disclosures: Ole De Backer has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of TCT 2022

Access more content on Atrial Fibrillation here and Interventional Cardiology here

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup